Talk Now: FDA Finalizes Guidance On Pre-Market Communications
This article was originally published in The Gray Sheet
Executive Summary
The guidance, which is very similar to a proposed version from last year, updates the interactive review program, and describes three relatively new points of communication between FDA and a device sponsor during the review process.
You may also be interested in...
FDA Emphasizes Pre-Submissions For Neuro Devices
Make pre-submissions early and as complete as possible to ensure speedy review and thorough answers for neurological devices, FDA staff says.
Big Uptick In Withdrawn 510(k)s Highlighted In Booz Allen Assessment
The consulting group issued its final assessment of FDA’s device review program following a year-long examination; it includes 11 recommendations for improvements. Among the new directives that were not included in Booz Allen’s interim report in December: FDA should perform a large study of withdrawn device submissions to figure out how to limit the growing practice.
Chatting With FDA: New Draft Guidance Addresses Communications During Device Reviews
The document updates FDA’s “interactive review” program, expanding uses of the approach and describing three additional types of review-process communications.